To the public, BioNTech is synonymous with the groundbreaking mRNA COVID-19 vaccine that changed the course of the pandemic. While that achievement secured the company's place in history and filled its coffers, it's a story that is rapidly becoming the prologue to a much larger narrative. In the company’s own words, BioNTech is executing a deliberate transformation into a “global immunotherapy powerhouse ” built to address the “full continuum of cancer.” Its third-quarter 2025 financial results tell this story not in press statements, but in hard numbers. This isn't a story about a potential shift years down the road; it's a pivot happening right now, fueled by historic profits and executed with clear financial discipline. For investors still viewing BioNTech through a COVID-19 lens, the latest earnings report is a critical wake-up call. Here are the four most important takeaways from the report that savvy investors need to understand. A Billion-Euro Revenue Boost Pai...